+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID07039604

Real-World Study of Percutaneous Pulmonary Artery Denervation Using Enhancor Radiofrequency Catheter to Treat Pulmonary Arterial Hypertension

Led by Pulnovo Medical (Wuxi) Co., Ltd. · Updated on 2025-06-26

200

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the use of percutaneous pulmonary artery denervation PADN as a treatment for pulmonary arterial hypertension PAH. It is a real-world observational study sponsored by Pulnovo Medical Wuxi Co., Ltd., focusing on patients diagnosed with PAH who have undergone the PADN procedure since March 2024. Participants will have undergone PADN using the Enhancor14 Radiofrequency Catheter. The procedure involves contrast pulmonary artery angiography to locate the pulmonary artery bifurcation, followed by radiofrequency ablation delivered circumferentially in specific pulmonary artery areas. After the procedure, patients without atrial fibrillation are recommended to take dual antiplatelet therapy for one month, while those with atrial fibrillation or metal valve replacements continue appropriate anticoagulant treatments as guided by their physician. During the study, participants will be monitored for clinical worsening over one year and assessed for changes in WHO functional class, NT-proBNPBNP levels, six-minute walk distance, echocardiographic changes, incidence of pulmonary infections, and all-cause death at intervals up to five years. The study involves long-term follow-up to track these outcomes and treatment effects in a real-world setting.

CONDITIONS

Brief Title

Real-World Study of PADN for the Treatment of PAH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here